DAXOR CORP DXR
manufacturing company which provides additional biotechnology services. Daxor Corporation was originally incorporated in New York
State as Iatric Corporation in May 1971 for cryobanking services and continues these services through its wholly-owned subsidiary,
Scientific Medical Systems. In October 1971, the name Iatric Corporation was changed to Idant Corporation. In May 1973, the name
Idant Corporation was changed to Daxor Corporation.
Valuation FY2011 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2011 | FY2010 | FY2009 |
|---|---|---|---|
| Revenue | $1.4M | $1.6M | — |
| Cost of revenue | $652.5K | $727.6K | — |
| Gross profit | $793.8K | $851.6K | — |
| R&D | $2.7M | $3.0M | — |
| SG&A | $3.9M | $3.5M | — |
| Total operating expenses | $6.6M | $6.5M | — |
| Operating income | -$5.8M | -$5.7M | — |
| Pre-tax income | -$2.0M | $8.4M | — |
| Income tax | $5.1M | $3.4M | — |
| Net income | -$7.2M | $5.0M | — |
| EPS, diluted | -1.70 | 1.17 | — |
Balance sheet
| Fiscal year | FY2011 | FY2010 | FY2009 |
|---|---|---|---|
| Cash and equivalents | $59.6K | $57.7K | $277.1K |
| Receivables | $219.7K | $178.8K | — |
| Inventory | $301.5K | $363.6K | — |
| Total current assets | $81.7M | $87.0M | — |
| Property, plant and equipment | $4.0M | $4.2M | — |
| Total assets | $85.7M | $91.2M | — |
| Accounts payable | $525.2K | $436.5K | — |
| Total current liabilities | $49.3M | $43.9M | — |
| Total liabilities | $49.5M | $44.2M | — |
| Retained earnings | $24.7M | $33.0M | — |
| Total equity | $36.2M | $47.0M | $47.6M |
Cash flow
| Fiscal year | FY2011 | FY2010 | FY2009 |
|---|---|---|---|
| Operating cash flow | -$6.5M | -$5.7M | — |
| Depreciation and amortisation | $290.8K | $296.6K | — |
| Stock-based compensation | $9.7K | — | — |
| Capital expenditure | $123.2K | $324.7K | — |
| Investing cash flow | -$11.4M | $9.4M | — |
| Financing cash flow | $17.9M | -$3.9M | — |
| Dividends paid | $1.1M | $4.2M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001019056-12-000401.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2009 | FY2010 | FY2011 |
|---|---|---|---|
| Revenue | — | $1.6M | $1.4M |
| Gross profit | — | $851.6K | $793.8K |
| Net income | — | $5.0M | -$7.2M |
Recent filings and events
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Other event Item 8.01
- Other event Item 8.01
- Shareholder vote Item 5.07
- Shareholder vote Item 5.07
- Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
- Other event Item 8.01
- Other event Item 8.01
- Other event Item 8.01
- Other event Item 8.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.